Changi General Hospital (CGH) and Moringa Ventures, a deep-tech venture builder backed by Tembusu Partners Pte Ltd, today announced the signing of a Memorandum of Understanding (MOU) to advance the validation, testing, and adoption of biomedical technologies within CGH’s clinical, research, and operational environments.

The collaboration establishes a structured pathway for translating promising technologies from proof-of-concept stages (TRL 3–4) to commercial readiness (TRL 8–9), leveraging CGH’s clinical expertise, infrastructure and real-world environments for clinically guided assessment and rigorous validation.

The partnership is open to innovations across the full spectrum of healthcare and biomedicine — from medical devices, diagnostics, therapeutics, and biotech to AI-driven clinical decision tools, digital tech and robotics solutions. CGH will play a central role, providing clinical insights to ensure solutions address genuine unmet needs, advising on workflows, patient pathways, operational requirements, product features, and safety requirements, and supporting the design and execution of validation activities and clinical protocols so that solutions are aligned with care delivery needs. Moringa Ventures will originate and build deep-tech healthcare startups through its venture platform, in close partnership with CGH to surface clinical needs, shape solutions, and validate them in real-world environments. Combining venture building with capital, Moringa supports founders from early development through to commercial adoption and scale.

Clinical Professor Ng Kee Chong, Chief Executive Officer, CGH, said: “Meaningful healthcare innovation must address unmet clinical needs, supported by a clear understanding of patient pathways, workflows and safety requirements. Through this collaboration with Moringa Ventures, CGH will support the validation of promising biomedical and deep-tech solutions that will transform care and better health. By working closely with innovators from an early stage, we aim to shape solutions that are relevant for healthcare-strengthening care delivery, supporting healthcare professionals, and enhancing patient outcomes.”

Ms Theodora Lai, Co-Founder and Partner, Moringa Ventures, said: “Asia is at an inflection point in healthcare. We have the scientific talent to develop novel diagnostics and therapeutics, the engineering depth to build AI and robotics systems that transform care delivery, and the clinical institutions to validate them at scale. What has been missing is the connective infrastructure — the structured environment where founders across all of these disciplines can test, iterate, and build with direct clinical input. That is what this partnership with CGH creates. We are not just backing individual companies. We are building the foundation for a new generation of healthcare innovation to emerge from this region.”

The partnership supports CGH’s drive to innovate and transform care for better health through discovering and deploying solutions that strengthen patient care and support healthcare providers. By combining CGH’s clinical insights and care delivery expertise with Moringa Ventures’ venture-building and investment capabilities, the collaboration aims to produce clinically relevant, scalable healthcare technologies with impact in Singapore and across the region.